Cyclacel Pharmaceuticals Inc
CYCC
Market Cap$2.35M
Close$
$12.16
433.4% upside
Current Fair Value
433.4% upsideUndervalued by 433.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.35 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.0 |
| Beta | 0.2 |
| Outstanding Shares | 1,318,257 |
| Avg 30 Day Volume | 35,501 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
ESG Score
No data
About Cyclacel Pharmaceuticals Inc
2,018 employees
CEO: Spiro Rombotis Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in cell cycle, transcriptional regulation and DNA damage response biology in cancer cells to develop innovative medicines. The transcriptional reg...